Completed

The Use of Low Dose Testosterone To Enhance Libido In Female Cancer Survivors: A Phase III Randomized, Placebo-Controlled, Double-Blind Crossover Study

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

therapeutic testosterone

+ placebo

DrugOther
Who is being recruted

Urogenital Diseases+3

+ Genital Diseases

+ Behavior

See all eligibility criteria
How is the trial designed

Supportive Care Study

Phase 3
Interventional
Study Start: April 2004
See protocol details

Summary

Principal SponsorAlliance for Clinical Trials in Oncology
Last updated: July 13, 2016
Sourced from a government-validated database.Claim as a partner

Study start date: April 1, 2004

Actual date on which the first participant was enrolled.

OBJECTIVES: Primary Determine the efficacy of low-dose testosterone, in terms of average intra-patient change in libido, in postmenopausal female cancer survivors with a decreased libido. Secondary Determine the toxic effects of this drug in these patients. Determine the levels of estrogen and testosterone and SGOT in patients reporting a decreased libido before and after treatment with this drug. Determine whether increasing libido significantly positively affects pleasure from sexual activity in patients treated with this drug. Determine the effect of this drug on vitality, general quality of life, and overall mood in these patients. OUTLINE: This is a double-blind, placebo-controlled, randomized, crossover, multicenter study. Patients are stratified according to antidepressant medication use (yes vs no), age (under 50 vs 50 to 60 vs 61 to 70 vs over 70), tamoxifen or other selective estrogen receptor modulator use (yes vs no), and ovarian status (in place [natural menopause or hysterectomy] vs not in place [bilateral oophorectomy]). Patients are randomized to 1 of 2 treatment arms. Arm I: Patients receive topical testosterone once daily for 4 weeks. Arm II: Patients receive a topical placebo once daily for 4 weeks. After 4 weeks, patients cross over to the other treatment arm. Changes in sexual functioning, mood states, and medical outcome vitality are assessed at baseline and then at the end of weeks 4 and 8. Patients who continue or restart testosterone cream after the 8-week study period are followed at 6 months.

NCT00075855
Principal SponsorAlliance for Clinical Trials in Oncology
Last updated: July 13, 2016
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

150 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Supportive Care Study

These studies explore ways to improve comfort and daily life for people living with a condition. They may focus on easing symptoms, reducing treatment side effects, or supporting overall well-being.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Female

Biological sex of participants that are eligible to enroll.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Urogenital DiseasesGenital DiseasesBehaviorSexual BehaviorSexual Dysfunction, PhysiologicalSexuality

Criteria

DISEASE CHARACTERISTICS: History of cancer No active disease Currently has a sexual partner Reports a decrease in sexual desire or libido and would like an intervention for it Defined as a score of less than 8 on the numerical analogue scale PATIENT CHARACTERISTICS: Age See Menopausal status Sex Female Menopausal status Postmenopausal, defined as the following: Surgically induced menopause OR absence of a period for at least 12 months (naturally or treatment-induced) Performance status ECOG 0-1 Hematopoietic WBC ≥ 2,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 10 g/dL No untreated anemia Hepatic SGOT ≤ 1.5 times upper limit of normal (ULN) No known liver disease Renal Creatinine ≤ 1.5 times ULN No renal dysfunction Cardiovascular No coronary artery disease No congestive heart failure Other No untreated hypothyroidism No diabetes No major depressive disorder requiring treatment PRIOR CONCURRENT THERAPY: Chemotherapy Concurrent cytotoxic chemotherapy (e.g., tamoxifen or aromatase inhibitors) allowed Endocrine therapy No prior testosterone No prior androgen agents for libido Concurrent selective estrogen receptor modulators allowed Concurrent vaginal estrogen allowed provided it was initiated ≥ 1 month ago and continued at the same dose during study participation Radiotherapy Concurrent radiotherapy allowed Surgery No prior major pelvic surgery resulting in anatomical changes to the vaginal anatomy Prior hysterectomy allowed Other Concurrent antidepressants for postmenopausal mood or hot flashes allowed provided patient is on a stable dose that will not change within the next 8 weeks No concurrent anticoagulants or propanolol Concurrent anticoagulants for central or peripheral line maintenance (e.g., warfarin 1 mg daily or heparin flushes) allowed No other concurrent treatment for decreased libido

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
Patients receive topical testosterone once daily for 4 weeks. After 4 weeks, patients cross over to the other treatment arm. Changes in sexual functioning, mood states, and medical outcome vitality are assessed at baseline and then at the end of weeks 4 and 8. Patients who continue or restart testosterone cream after the 8-week study period are followed at 6 months.

Group II

Patients receive a topical placebo once daily for 4 weeks. After 4 weeks, patients cross over to the other treatment arm. Changes in sexual functioning, mood states, and medical outcome vitality are assessed at baseline and then at the end of weeks 4 and 8. Patients who continue or restart testosterone cream after the 8-week study period are followed at 6 months.

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 16 locations

CCOP - Mayo Clinic Scottsdale Oncology Program

Scottsdale, United StatesOpen CCOP - Mayo Clinic Scottsdale Oncology Program in Google Maps

Mayo Clinic - Jacksonville

Jacksonville, United States

CCOP - Carle Cancer Center

Urbana, United States

CCOP - Cedar Rapids Oncology Project

Cedar Rapids, United States
Completed16 Study Centers